Earnings

Zenas BioPharma Q3 EPS $(1.65) Misses $(1.33) Estimate, Sales $10.000M

Nov 5, 2026 · 07:51 AM ET· updated 2h ago

Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(1.33) by 24.06 percent. This is a 35.25 percent decrease over losses of $(1.22) per share

Why It Matters

Zenas BioPharma lost more money per share than experts thought it would. When a company's losses grow bigger, watch to see if they're getting closer to making real money.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ZBIO27.39

-1.07 (-3.76%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.